Tracon Pharmaceuticals, Inc., a biopharmaceutical company, has filed Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024, to deregister unsold securities under four previous registration statements. The affected registration statements include those filed on May 10, 2018, September 4, 2020, March 16, 2022, and March 16, 2023, which collectively registered shares for resale by selling stockholders and for sale up to $150 million in common stock. The deregistration follows the company's board of directors' approval of a plan of dissolution on July 30, 2024, subject to stockholder approval, leading to the decision to terminate the offerings of the securities and remove any unsold securities from registration. The share numbers have been adjusted to reflect two reverse stock splits, one on November 7, 2019, and another on April 10, 2024. The company's President and Chief Executive Officer, Craig R. Jalbert, signed the amendment, which effectively ends the availability of these securities for public sale.

Tracon Pharmaceuticals, Inc., a biopharmaceutical company, has filed Post-Effective Amendment No. 1 with the U.S. Securities and Exchange Commission (SEC) on October 31, 2024, to deregister unsold securities under four previous registration statements. The affected registration statements include those filed on May 10, 2018, September 4, 2020, March 16, 2022, and March 16, 2023, which collectively registered shares for resale by selling stockholders and for sale up to $150 million in common stock. The deregistration follows the company's board of directors' approval of a plan of dissolution on July 30, 2024, subject to stockholder approval, leading to the decision to terminate the offerings of the securities and remove any unsold securities from registration. The share numbers have been adjusted to reflect two reverse stock splits, one on November 7, 2019, and another on April 10, 2024. The company's President and Chief Executive Officer, Craig R. Jalbert, signed the amendment, which effectively ends the availability of these securities for public sale.